38 Week Extension Study to CAIN457C2303

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Uveitis

In brief

A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet's patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy

Key facts

Study ID
NCT01093846
Run by
Novartis Pharmaceuticals
People needed
59
Starts
2010-03-01
Expected to finish
2011-01-01
Last updated by the study team
2016-02-22

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.